Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05852223
Title Pembrolizumab in High-risk Thyroid Cancer (NePenThe)
Acronym NePenThe
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Istituti Clinici Scientifici Maugeri SpA
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST